Histogen Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HSTO research report →
Companywww.histogen.com
Histogen Inc. , a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19.
- CEO
- Susan A. Knudson
- IPO
- 2013
- Employees
- 7
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $85.44K
- P/E
- -0.01
- P/S
- 0.02
- P/B
- 0.00
- EV/EBITDA
- 0.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -282.38%
- Net Margin
- -281.80%
- ROE
- -59.67%
- ROIC
- -58.85%
Growth & Income
- Revenue
- $3.77M · 310.12%
- Net Income
- $-10,621,000 · 28.96%
- EPS
- $-3.46 · 53.93%
- Op Income
- $-10,643,000
- FCF YoY
- 32.99%
Performance & Tape
- 52W High
- $0.02
- 52W Low
- $0.02
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.12
- Avg Volume
- 0
Get TickerSpark's AI analysis on HSTO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 20, 23 | Windham-Bannister Susan Richards | other | 6,835 |
| Jun 20, 23 | Satz Brian | other | 6,835 |
| Jun 20, 23 | KISNER DANIEL L | other | 6,835 |
| Jun 20, 23 | Jackson Jonathan | other | 6,835 |
| Jun 20, 23 | Fuhrmann Rochelle | other | 6,835 |
| Jun 20, 23 | Crean David Hugh | other | 6,835 |
| Mar 10, 23 | Reyes Joyce | other | 47,417 |
| Mar 10, 23 | Reyes Joyce | other | 16,659 |
| Mar 10, 23 | Reyes Joyce | sell | 4,452 |
| Mar 10, 23 | Reyes Joyce | sell | 7,833 |
Our HSTO Coverage
We haven't published any research on HSTO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HSTO Report →